Marvel Biosciences Corp (TSE:MRVL) has released an update.
Marvel Biosciences Corp. has partnered with the FRAXA Research Foundation to test its lead compound, MB204, in a preclinical model for Fragile X syndrome, a condition linked to autism and intellectual disabilities. With no current approved treatment for FXS, the novel MB204, a derivative of an anti-Parkinson’s drug, shows promise in addressing this genetic disorder as well as possibly benefiting autism spectrum disorder and other neurological conditions.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.
